1 Desai, A., Sandhu, S., Lai, J. P. & Sandhu, D. S., Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World J Hepatol 11 1 (2019).
2 Kamiyama, T. et al., Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma. WORLD J SURG ONCOL 10 107 (2012).
3 Huang, D. et al., Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer. TARGET ONCOL 15 93 (2020).
4 van den Bulk, J., Verdegaal, E. M. & de Miranda, N. F., Cancer immunotherapy: broadening the scope of targetable tumours. OPEN BIOL 8 (2018).
5 Hsu, Y. C. et al., Tumor mutation burden and recurrent tumors in hereditary lung cancer. Cancer Med 8 2179 (2019).
6 Lee, D. W. et al., Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. CLIN CANCER RES 25 6141 (2019).
7 Riggs, M. J. et al., DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. PLOS ONE 15 e244558 (2020).
8 Jang, B. S., Han, W. & Kim, I. A., Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer. RADIOTHER ONCOL 142 202 (2020).
9 Steuer, C. E. & Ramalingam, S. S., Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? J CLIN ONCOL 36 631 (2018).
10 Yu, Q. J., Liang, Y. Z., Mei, X. P. & Fang, T. Y., Tumor mutation burden associated with miRNA-gene interaction outcome mediates the survival of patients with liver hepatocellular carcinoma. EXCLI J 19 861 (2020).
11 Cai, H. et al., Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy. J SURG ONCOL 121 1007 (2020).
12 Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P., Maftools: efficient and comprehensive analysis of somatic variants in cancer. GENOME RES 28 1747 (2018).
13 Walter, W., Sanchez-Cabo, F. & Ricote, M., GOplot: an R package for visually combining expression data with functional analysis. BIOINFORMATICS 31 2912 (2015).
14 Tang, Z. et al., GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. NUCLEIC ACIDS RES 45 W98 (2017).
15 Robinson, M. D., McCarthy, D. J. & Smyth, G. K., edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. BIOINFORMATICS 26 139 (2010).
16 Xie, F. et al., Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. INT IMMUNOPHARMACOL 89 107135 (2020).
17 Wu, L., Zheng, J., Chen, P., Liu, Q. & Yuan, Y., Small nucleolar RNA ACA11 promotes proliferation, migration and invasion in hepatocellular carcinoma by targeting the PI3K/AKT signaling pathway. BIOMED PHARMACOTHER 90 705 (2017).
18 He, G. & Karin, M., NF-kappaB and STAT3 - key players in liver inflammation and cancer. CELL RES 21 159 (2011).
19 Ruiz, D. G. M. et al., beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. CANCER DISCOV 9 1124 (2019).
20 Yarchoan, M., Hopkins, A. & Jaffee, E. M., Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377 2500 (2017).
21 Tanaka, S. et al., Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. CANCER RES 53 2884 (1993).
22 Toshikuni, N., Matsue, Y., Minato, T., Hayashi, N. & Tsutsumi, M., Association between transforming growth factor-beta1 -509 C>T variants and hepatocellular carcinoma susceptibility: a meta-analysis. NEOPLASMA 63 961 (2016).
23 Sghaier, I. et al., TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection. Br J Biomed Sci 76 35 (2019).
24 Zhang, L. Y. et al., Targeting Tumor Immunosuppressive Microenvironment for the Prevention of Hepatic Cancer: Applications of Traditional Chinese Medicines in Targeted Delivery. CURR TOP MED CHEM 20 2789 (2020).
25 Wang, S. S. et al., Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway. CELL DEATH DIS 8 e2688 (2017).
26 Wong, C. M., Tsang, F. H. & Ng, I. O., Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol 15 137 (2018).
27 Yao, Z. et al., ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. MOL ONCOL 11 422 (2017).
28 Wu, J. et al., Bioinformatic Analysis of Circular RNA-Associated ceRNA Network Associated with Hepatocellular Carcinoma. BIOMED RES INT 2019 8308694 (2019).
29 Wu, Q. et al., Tumor suppressor role of sFRP4 in hepatocellular carcinoma via the Wnt/betacatenin signaling pathway. MOL MED REP 23 (2021).
30 Zenatti, P. P. et al., Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. NAT GENET 43 932 (2011).
31 Kong, F. et al., Hepatitis B virus X protein promotes interleukin-7 receptor expression via NF-kappaB and Notch1 pathway to facilitate proliferation and migration of hepatitis B virus-related hepatoma cells. J Exp Clin Cancer Res 35 172 (2016).
32 Zhang, B. & Wu, H., Decreased expression of COLEC10 predicts poor overall survival in patients with hepatocellular carcinoma. CANCER MANAG RES 10 2369 (2018).
33 Zheng, J. et al., MiR-452-5p mediates the proliferation, migration and invasion of hepatocellular carcinoma cells via targeting COLEC10. Per Med 18 97 (2021).
34 Spadaro, A. et al., Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 11 1987 (2005).